PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

Mayo Clinic

Status and phase: Completed; Phase 2; Phase 1

Conditions: Cancer

Treatments: Diagnostic Test: PET/CT; Drug: radioactive drug (tracer)

Study type: Interventional

Funder types: Other

Identifiers

NCT04538950

19-009189

Details and patient eligibility

About

Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.

Enrollment: 6 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• First time administration of ICI
• Willing and able to return in 4-6 weeks for follow-up study
• Patients with previous heart conditions included (while this may impact MFR the delta MFR is what we are assessing)

Exclusion criteria

• Age < 18 years
• Women who are pregnant, or breast-feeding.
• Unable or unwilling to give consent to undergo PET/CT.

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Checkpoint Inhibitor (ICI)

Other group

Description:

Subjects diagnosed with cancer and will be receiving immune checkpoint inhibitors as treatment standard of care will have a PET/CT scan before and after therapy. PET/CT scan is done for study purposes only.

Treatment:

Drug: radioactive drug (tracer)

Diagnostic Test: PET/CT